263
Participants
Start Date
August 17, 2016
Primary Completion Date
September 1, 2017
Study Completion Date
April 16, 2018
MV-CHIK low dose
recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection, 5xE4 (± 0.5 log) TCID50/dose
MV-CHIK high dose
recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection; 5xE5 (± 0.5 log) TCID50/dose
Priorix®
lyophilized mixed preparation containing the attenuated Schwarz measles virus strain, the RIT 4385 strain of mumps virus (derived from the Jeryl Lynn strain) and the Wistar RA 27/3 rubella virus strain. Powder and solvent for suspension for injection
physiological saline solution
sterile physiological saline solution 0.9% used as placebo
Medical University Vienna, Department of Clinical Pharmacology, Vienna
Hansa Sanatorium GmbH, Graz
Berliner Center for Travel- and Tropical Medicine, Berlin
Medicinal University Rostock, Department for Tropical Medicin and infectious diseases, Rostock
Themis Bioscience GmbH
INDUSTRY